GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
‘I dreamed of moving to Malta 20 years ago’: iQrypto CEO
Quantum tech firm iQrypto is set to expand its operations to Malta.
Edmond Bonett returns to Manouche as CEO
'There is a lot to do – let’s get to work.'
Black Sea, Hormuz attacks on merchant ships ‘a breakdown of the international order’ – MMF Chair
Malta Flagged vessel M/V Chelsea-3 was struck by three drones whilst sailing in the Black Sea.
‘Growing number of British businesses looking to partner with Maltese firms’ – TradeMalta CEO
Tania Brown say British businesses increasingly seeking partnerships with Maltese firms.
